Trial Profile
A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies [Ensayo multicentrico, abierto y de extension para evaluar la seguridad y la eficacia de AD 923 (Fentanilo sublingual) en el tratamiento del dolor irruptivo en sujetos con procesos malignos]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2013
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- 17 Mar 2012 Planned end date changed from 21 Apr 2009 to 1 Mar 2009 as reported by European Clinical Trials Database.
- 18 Aug 2011 New trial record